Fig. 2
From: HDAC5 inhibition attenuates ventricular remodeling and cardiac dysfunction
LMK235 ameliorates cardiac dysfunction induced by TAC in vivo
(A) Experimental procedure for injecting mice with LMK235. (B) Representative images of M-mode echocardiography of mice in each group. (C, D, E, F) Echocardiographic parameters include left ventricular ejection fraction (LVEF), left ventricular shortening fraction (LVFS), left ventricular end-diastolic diameter (LVIDd), and left ventricular end-systolic diameter (LVIDs) (n = 6 for each group). (G) Representative Doppler echocardiographic images of mitral flow in each group. (H) Mitral inflow velocities (E/A). (I) Isovolumic relaxation time (IVRT) (n = 3 for each group). Data are presented as means ± SD, *P < 0.05; **P < 0.01